Ratings BioLineRx Ltd.

Equities

BLRX

IL0011015182

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 04:49:33 09/05/2024 pm IST			5-day change	1st Jan Change
16.5 ^ILa	0.00%		+9.27%	-56.81%

17/04	BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting	CI
10/04	BioLineRx Ltd. Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
BIOLINERX LTD.	-56.81%	53.23M	-
VERTEX PHARMACEUTICALS INCORPORATED	+2.93%	108B	B+
REGENERON PHARMACEUTICALS, INC.	+8.82%	105B	B+
ARGENX SE	+0.90%	23.46B	B
BIONTECH SE	-14.60%	21.72B	B+
GENMAB A/S	-7.05%	18.64B	A-
WUXI APPTEC CO., LTD.	-38.55%	17.45B	A-
BEIGENE, LTD.	-8.83%	17.19B	B
NEUROCRINE BIOSCIENCES, INC.	+5.51%	13.99B	C+
SAREPTA THERAPEUTICS, INC.	+37.49%	12.53B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes